As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

For Mounjaro, the diabetes treatment ... indicative of a long-term problem for the business. Eli Lilly still has a couple of fantastic drugs in Mounjaro and Zepbound, which could generate a ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Shares of Eli Lilly & Co. were headed for their ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared to ...

The analysis of 2.4mn patients bolsters research into how blockbuster drugs for obesity and diabetes such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro could have significant ...